NPPA's move to put price control on more drugs to hurt pharma industry
The fresh move to bring diabetes and cardiovascular medicines under price control regime could result in a loss of around Rs 600 crore to the industry
BS B2B Bureau B2B Connect | Chennai
)
More than the loss, the industry is worried that this would be a trend in the coming days. The price control is by invoking a clause in Paragraph 19 of DPCO, 2013, which empowers NPPA to fix a ceiling or retail price of a drug ‘in extraordinary circumstances’, for the public interest.
“It came as a shock to us. We are afraid that this would set a precedence and the government can bring in control on more drugs using the clause in future, which would leave us in a situation where we don’t have a breathing space,” said Veerramani. He said that the association has submitted a representation to the Department of Pharmaceuticals and approached NPPA, asking them to hold the decision till the association would look into it.
Also Read
The DPCO 2013, which came into effect in the second half of last year has resulted in a loss of around Rs 1000 crore and the industry was slowly recovering from its impact, when the new price control decision hit it again, he said. The industry growth has come down from 12-15% to 6% last year owing to the drug price control across 348 formulations under the DPCO.
The NPPA has fixed the prices 108 non-scheduled formulation packs 50 drugs in antidiabetic and cardiovascular segment, in respect of under Paragraph 19 of DPCO, 2013 through an order dated on July, 2014.
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jul 21 2014 | 1:43 PM IST